Stock Market Reviews

XFOR (X4 Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on XFOR (X4 Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Company’s strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trialPreviously announced workforce reductions resulted in $13M annualized cost savingsSuccessful completion of two financial transactions totaling $240.3M; cash runway now extends to the end of 2028 BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today reported financial results
  Nov 5, 2025 - $XFOR
• X4 Pharmaceuticals: Q3 Earnings Snapshot
  BOSTON (AP) — X4 Pharmaceuticals, Inc. XFOR) on Wednesday reported a loss of $29.8 million in its third quarter. The Boston-based company said it had a loss of 69 cents per share.
  Nov 5, 2025 - $XFOR
• X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference
  BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Second Annual Healthcare Innovation Conference on November 10-12, 2025 in Boston. The X4 team will hold a fireside chat on November 10th at 8:30 a.m. ET and will be available for one-on-one meetings with investors. A webcast of the fireside chat will be avail
  Nov 5, 2025 - $XFOR
• Techne (TECH) Meets Q1 Earnings Estimates
  Techne (TECH) delivered earnings and revenue surprises of 0.00% and -0.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $XFOR
• MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
  MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Nov 5, 2025 - $XFOR
• X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
  BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the closing of its previously announced underwritten public offering of 52,844,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 6,984,000 additional shares, at a public offering price per share of $2.90 and, in lieu of common stock to certain inve
  Oct 27, 2025 - $XFOR
• X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
  BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its previously announced underwritten public offering of 45,860,000 shares of its common stock at a public offering price per share of $2.90 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at a public offering pri
  Oct 24, 2025 - $XFOR
• X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
  BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, X4 expects to grant the underwriters an option for a period of 30 days to purchase
  Oct 23, 2025 - $XFOR
• X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?
  X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Oct 22, 2025 - $XFOR
• Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
  Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chie
  Sep 29, 2025 - $XFOR